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Salicylate Downregulates 11b-HSD1 Expression in
Adipose Tissue in Obese Mice and in Humans,
Mediating Insulin Sensitization
Mark Nixon, Deborah J. Wake, Dawn E. Livingstone, Roland H. Stimson, Cristina L. Esteves,
Jonathan R. Seckl, Karen E. Chapman, Ruth Andrew, and Brian R. Walker
Recent trials show salicylates improve glycemic control in type 2
diabetes, but the mechanism is poorly understood. Expression of
the glucocorticoid-generating enzyme 11b-hydroxysteroid dehy-
drogenase type 1 (11b-HSD1) in adipose tissue is increased in
vitro by proinﬂammatory cytokines and upregulated in obesity.
11b-HSD1 inhibition enhances insulin sensitivity. We hypothesized
that salicylates downregulate 11b-HSD1 expression, contributing
to their metabolic efﬁcacy. We treated diet-induced obese (DIO)
11b-HSD1–deﬁcient mice and C57Bl/6 mice with sodium salicylate
for 4 weeks. Glucose tolerance was assessed in vivo. Tissue tran-
script levels were assessed by quantitative PCR and enzyme activ-
ity by incubation with 3H-steroid. Two weeks’ administration of
salsalate was also investigated in a randomized double-blind pla-
cebo-controlled crossover study in 16 men, with measurement of
liver 11b-HSD1 activity in vivo and adipose tissue 11b-HSD1 tran-
script levels ex vivo. In C57Bl/6 DIO mice, salicylate improved
glucose tolerance and downregulated 11b-HSD1 mRNA and activ-
ity selectively in visceral adipose. DIO 11b-HSD1–deﬁcient mice
were resistant to these metabolic effects of salicylate. In men,
salsalate reduced 11b-HSD1 expression in subcutaneous adipose,
and in vitro salicylate treatment reduced adipocyte 11b-HSD1 ex-
pression and induced adiponectin expression only in the presence
of 11b-HSD1 substrate. Reduced intra-adipose glucocorticoid re-
generation by 11b-HSD1 is a novel mechanism that contributes to
the metabolic efﬁcacy of salicylates. Diabetes 61:790–796, 2012
Salicylate anti-inﬂammatory agents, including ace-tylsalicylic acid (aspirin) and salicylsalicylic acid(salsalate) (1), improve insulin sensitivity in ani-mal models (2–5) and in healthy or obese humans
(6–9) and improve glycemic control in patients with type
2 diabetes (10–12). The mechanism of insulin sensitiza-
tion is uncertain and may involve blockade of inhibitor of kB
kinase-b and, hence, nuclear factor-kB effects (13,3,14)
and/or interference with phosphorylation and activity of
CCAAT enhancer binding protein-b (a transcription factor
involved in metabolic and inﬂammatory pathways) (15,16),
with associated reductions in proinﬂammatory cytokines.
11b-Hydroxysteroid dehydrogenase type 1 (11b-HSD1)
catalyzes the regeneration of active cortisol from inert
cortisone (corticosterone from 11-dehydrocorticosterone
in rodents), including in liver and adipose tissue (17). In
genetically modiﬁed mice, overexpression of 11b-HSD1 in
adipose tissue (18) or liver (19) results in increased glu-
cocorticoid action and insulin resistance, whereas targeted
disruption of Hsd11b1 protects against insulin resistance
and central obesity on high-fat feeding (20–22). Pharma-
cological inhibition of 11b-HSD1 lowers intracellular glu-
cocorticoid levels and thereby enhances insulin sensitivity
in rodents and humans (23–26). Circumstantial evidence
suggests that salicylates may reduce 11b-HSD1 in adipose
tissue. Proinﬂammatory cytokines, including tumor necrosis
factor (TNF)-a, interleukin-1b, and interleukin-6, upre-
gulate 11b-HSD1 in several cell types in culture, including
in human preadipocytes (27–29). In human obesity, a state
of systemic and intra-adipose inﬂammation (14), 11b-HSD1
mRNA levels and activity are decreased in liver (30,31) but
increased in subcutaneous adipose tissue (32,31,33)—
reviewed in (34)—and less consistently in visceral adipose
tissue (35,36), explaining elevated intra-adipose cortisol
regeneration (37). These observations raise the possibility
that intra-adipose 11b-HSD1 expression is increased by the
proinﬂammatory state in obesity. Indeed, in HIV lipodys-
trophy, a paradigm of extreme intra-adipose inﬂammation,
there is increased intra-adipose and systemic 11b-HSD1
activity (38).
We hypothesized that salicylates reduce 11b-HSD1 ex-
pression in adipose tissue and that this contributes to their
insulin-sensitizing effect. We examined the effects of sa-
licylate on adipose tissue 11b-HSD1 in vivo in lean and
obese mice and humans.
RESEARCH DESIGN AND METHODS
Chemicals were purchased from Sigma-Aldrich (Dorset, U.K.) unless otherwise
stated.
Cell culture experiments. Simpson-Golabi-Behmel syndrome (SGBS) cells
are a human preadipocyte cell line characterized by a high capacity for in vitro
differentiation (39). Cells were cultured in Dulbecco’s modiﬁed Eagle’s medium–
F12, supplemented with 10% (v/v) FCS, 50 units/mL penicillin per 50 units/mL
streptomycin, biotin (33 mmol/L), and pantothenic acid (17 mmol/L) at 37°C in
5% CO2. Adipogenic differentiation was induced after reaching near conﬂu-
ence as described previously (39). At day 14, cells were incubated for 24 h
in stripped serum medium prior to treatment with salicylic acid (10, 30, and
100 mmol/L) or vehicle (0.1% ethanol) for 24 h, and RNA was extracted for
analysis of 11b-HSD1 transcript. To assess the interaction between salicylate
and 11b-HSD1 in determining adiponectin (AdiQ) transcript levels, day 14 cells
were incubated for 24 h in cortisol-free, stripped serum medium prior to
treatment with cortisol (0.1 mmol/L), cortisone (0.1 mmol/L), or vehicle (0.1%
ethanol) with or without salicylic acid alone (100 mmol/L), or vehicle (0.1%
ethanol) for 24 h. RNA was extracted for analysis.
Experiments in mice. Experiments were performed under license from the U.K.
Home Ofﬁce. Mice were maintained under controlled conditions of light (0700–
1900 h) and temperature (18–20°C) and allowed access to food and drinking
water ad libitum. Adult male C57Bl/6 mice were obtained (Harlan Olac,
Oxfordshire, U.K.) at age 12 weeks. C57Bl/6 Lean animals were maintained on
normal chow diet (2.27% fat, 4.05% sucrose; 801151; Special Diet Services). Diet-
induced obese C57Bl/6 mice (C57Bl/6 DIO) were given 10 weeks of high-fat diet
(58% fat, 12% sucrose; D12331; Research Diets, New Brunswick, NJ) before
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treatment. Homozygous male 11b-HSD1–deﬁcient (HSD1KO) mice were
bred from an in-house colony on a C57Bl/6 background (.10 generations
backcross) (21) and fed a high-fat diet until weight matched with C57Bl/6
DIO mice (;38 g).
Sodium salicylate (salicylate) (120 mg/kg/day) or distilled water (vehicle)
was administered from 1 week after arriving (C57Bl/6 Lean), after 10 weeks of
high-fat feeding (C57Bl/6 DIO), or after achieving target weight (HSD1KO-
DIO) for 4 weeks to groups of n = 8 via osmotic minipumps implanted sub-
cutaneously between the scapulae.
For glucose tolerance tests, micewere fasted for 6 h before administration of
glucose (2 g/kg) by intraperitoneal injection and blood sampling by tail nicks for
90 min thereafter.
Animals were killed by decapitation and tissues dissected onto dry ice and
stored at 280°C until analysis.
Experiments in humans. A total of 16 otherwise healthy men, selected to
represent a wide range of BMIs, from 20 to 50 kg/m2, took part in a double-blind
balanced randomized crossover study to compare salsalate (Disalcid; 3M
Pharmaceuticals, Northridge, CA; 1 g p.o. every 8 h for 2 weeks) with placebo.
There was a 2-week washout period between phases, consistent with the short
half-life of salsalate (,8 h). Inclusion criteria included normal thyroid, renal,
and hepatic function; alcohol intake ,28 units/week; no glucocorticoid use in
the previous 6 months; no medication, including nonsteroidal anti-inﬂammatory
medication in the previous month or during the study; and no history of dys-
pepsia or peptic ulcer disease. Local ethical committee approval and written
informed consent were obtained.
At the end of each phase, volunteers attended the clinical research facility on
2 consecutive days. On day 1, they completed a 24-h urine collection and
attended at 0830 h after fasting overnight. Blood was taken for glucose, insulin,
lipid proﬁle, and plasma cortisol. Height, weight, waist, and hip circumferences;
percent fat by bioimpedance (Omron BF302, Milton Keynes, U.K.); and blood
pressure by mercury sphygmomanometer were recorded. An adipose biopsy
was obtained from periumbilical subcutaneous adipose tissue under local
anesthesia (lignocaine 1%; Braun; Shefﬁeld, U.K.) using a 14G biopsy needle
(Sterican; B. Braun Melsungen AG) attached to a sterile 60 mL syringe. The
tissue was then washed with diethyl pyrocarbonate–treated water, frozen
immediately on dry ice, and stored at 280°C.
On day 2, volunteers took oral dexamethasone 1mg (Merck Sharp &Dohme,
Hertsfordshire, U.K.) at 2300 h the evening before, fasted overnight, and
attended at 0900 h. A venous cannula was inserted and oral cortisone acetate
25 mg (Pantheon Inc., Swindon, U.K.) was administered with water. Plasma
samples were collected at intervals shown in Fig. 5 in lithium heparin and
stored at 220°C.
Laboratory methods
Biochemical assays. Mouse glucose and insulin were measured by hexo-
kinase assay (Thermo Electron, Victoria, Australia) and ELISA (Crystal Chem
Inc., Downers Grove, IL), respectively.
Human plasma cortisol was measured using the ImmunChem cortisol 125I
radioimmunoassay coated tube kit (MP Biomedicals, High Wycombe, U.K.).
Enzyme immunoassays (Eurogenetics Tasah Corp. UK Ltd., Hampton, U.K.)
were used to measure plasma insulin and C-peptide. Electrolytes and salicylate
were measured by dry-slide chemistry with a Vitros 950 (Ortho Clinical Diag-
nostics, Raritan, NJ), and glucose was determined on a Cabas Mira Plus (Roche,
Mannheim, Germany). Triglycerides, total cholesterol, and HDL cholesterol were
measured using ELISA kits (TG, CHOL, and HDLC-plus, respectively; Roche).
Human urinary cortisol and its metabolites (5b-tetrahydrocortisol [THF],
5a-THF, 5b-tetrahydrocortisone [THE], cortols, cortolones, and cortisone)
were measured in 24-h samples by electron impact gas chromatography/mass
spectrometry as previously described (40). The balance between 11b-HSD
activities in all tissues was assessed as the ratio of (5b-THF + 5a-THF) to THE.
Quantiﬁcation of mRNA. For cultured cells and mouse tissue samples, total
RNAwas extracted using TRIzol reagent (Invitrogen, Paisley, U.K.) and RNeasy
Mini Kit (QIAGEN,West Sussex, U.K.). RNA integrity was veriﬁed on an agarose
gel (1.2% w/v in 0.53 Tris/borate/EDTA). RNA (0.25 mg) was reverse tran-
scribed with random primers using the QuantiTect Reverse Transcription Kit
(QIAGEN). Real-time PCR was performed using the Roche LightCycler 480
(Roche Applied Science, Burgess Hill, U.K.). Primers (Invitrogen) were designed
for use with intron-spanning probes within the Roche Universal Probe Library.
Results from adipose tissue from lean and obese mice were corrected for
abundance of 18S and/or TATA binding protein mRNA, which were not af-
fected by treatment. Results from SGBS cells were corrected for abundance of
TATA-binding protein mRNA, which was not affected by treatment. All sam-
ples were analyzed in triplicate and ampliﬁcation curves plotted (y-axis ﬂuo-
rescence, x-axis cycle number). Triplicates were deemed acceptable if the SD
of the crossing point was ,0.5 cycles. A standard curve (y-axis crossing point,
x-axis log concentration) for each gene was generated by serial dilution of
cDNAs pooled from different samples, ﬁtted with a straight line, and deemed
acceptable if reaction efﬁciency was between 1.7 and 2.1.
For human adipose tissue, 100 mg tissue was homogenized and RNA
extracted using the QIAGEN RNeasy Lipid Tissue Mini kit (West Sussex, U.K.)
and quantiﬁed using the Ribogreen quantitation kit (Molecular Probes, Eugene,
OR). RNA integrity was veriﬁed on a 1.2% agarose/Tris borate/EDTA gel. Oligo
dT-primed cDNA was synthesized from 0.5 mg RNA using Promega Reverse
Transcription System (Promega, Southampton, U.K.), together with controls
from which reverse transcriptase was omitted. Transcript quantiﬁcation was
performed as above for mouse samples. Primer-probe sets for cyclophilin A
and 11b-HSD1 were purchased from Applied Biosystems (Cheshire, U.K.). Ran-
dom primers were used for 18S. The results are expressed as a ratio to the mean
of cyclophilin A and 18S, as internal controls that did not differ between groups.
Enzymology. 11b-HSD1 functions as a reductase in vivo, converting inactive
11-dehydrocorticosterone to corticosterone. However, in vitro, dehydrogenase
activity predominates, so velocity of 11b-HSD1 activity in adipose was quan-
tiﬁed through conversion of corticosterone to 11-dehydrocorticosterone. En-
zyme kinetics were determined from whole-adipose tissue homogenate.
Standardized amounts of protein for each tissue (mesenteric adipose 300 mg/mL;
subcutaneous adipose 100 mg/mL) were incubated (37°C) in Krebs-Ringer
buffer containing glucose (1% w/v), NADP (2 mmol/L), [3H]4-corticosterone
(10 nmol/L), and unlabeled corticosterone (9.99 mmol/L). Steroids were ex-
tracted after incubation (mesenteric adipose 24 h; subcutaneous adipose 22 h)
with ethyl acetate, the organic phase was evaporated under nitrogen, and ex-
tracts were solubilized in the mobile phase (water to acetonitrile to methanol;
60:15:25, 1.5 mL/min). Steroids were separated by high-performance liquid
chromatography using a C18 Sunﬁre column (Waters, Hertfordshire, U.K.) at
42°C and quantiﬁed by on-line liquid scintillation counting.
Statistical analyses. Results are presented as mean 6 SEM and analyzed by
Student t tests or two-way ANOVA with Bonferroni post hoc tests, as indicated
in the ﬁgure legends. Incremental changes induced by salsalate (i.e., value
after salsalate minus value after placebo) were correlated with indices of
obesity and plasma salsalate concentrations using Pearson correlation tests.
RESULTS
Salicylate improves glucose tolerance in obese but
not lean mice. Ten weeks of high-fat feeding caused diet-
induced obesity in male C57Bl/6 DIO mice, with elevated
fasting plasma insulin levels compared with C57Bl/6 Lean
mice (Table 1). On glucose tolerance testing, C57Bl/6 DIO
mice were hyperglycemic and hyperinsulinemic compared
with C57Bl/6 Lean mice, indicating development of insulin
resistance (Table 1 and Fig. 1).
Four weeks of treatment with salicylate (120 mg/kg/day)
had little measurable effect in C57Bl/6 Lean mice, except
for elevated fasting plasma insulin. In C57Bl/6 DIO mice,
salicylate decreased both fasting and postprandial plasma
glucose levels (Table 1 and Fig. 1). Furthermore, there was
a trend to reduced plasma triglyceride levels after salicy-
late treatment in C57Bl/6 DIO mice (P = 0.059) (Table 1).
Salicylate downregulates visceral adipose 11b-HSD1
in DIO mice. Salicylate signiﬁcantly reduced 11b-HSD1
mRNA in omental adipose tissue in C57Bl/6 DIO mice, with
a similar trend in mesenteric adipose (P = 0.057) (Fig. 2A).
In mesenteric adipose of C57Bl/6 DIO mice, salicylate also
reduced 11b-HSD1 enzyme activity (Fig. 2B).
11b-HSD1 deﬁciency blocks insulin-sensitizing ef-
fects of salicylate. HSD1KO-DIO mice were protected
against fasting hyperinsulinemia compared with weight-
matched C57Bl/6 DIO controls. However, HSD1KO-DIO mice
were still hyperinsulinemic, both fasting and postprandial,
compared with C57Bl/6 Lean mice (Table 1 and Fig. 1). In
marked contrast to C57Bl/6 DIO mice, salicylate had no
effects on biochemical indices in HSD1KO-DIO mice (Table 1
and Fig. 1).
11b-HSD1 deﬁciency prevents salicylate-induced
changes in adipose transcript levels. In C57Bl/6 DIO
mice (Fig. 3), salicylate altered mRNA levels of several
genes. In mesenteric adipose (Fig. 3B), salicylate in-
creased AdiQ and decreased TNF-a, monocyte chemo-
attractant protein-1 (MCP-1), adipose triglyceride lipase
(ATGL), and angiotensinogen (AGT) mRNA levels. This
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pattern of salicylate-induced changes was similar in omen-
tal adipose (Fig. 3A). With the exception of increasing AdiQ
mRNA levels, these effects were absent in subcutaneous
adipose tissue (Fig. 3C).
Compared with salicylate-treated C57Bl/6 DIO mice,
HSD1KO-DIO mice had a similar pattern of transcript
changes in visceral adipose, with increased AdiQ and re-
duced TNF-a and ATGL mRNA levels (Fig. 3). However, in
HSD1KO-DIO mice, salicylate treatment did not alter mRNA
levels of any of the genes affected in C57Bl/6 DIO mice
(Fig. 3).
Salsalate downregulates adipose 11b-HSD1 in vivo in
men. Characteristics of the 16 male participants are shown
in Table 2. Salicylate levels in plasma averaged 134 6 33
mg/L during active treatment and were undetectable during
placebo. Only 1 of the participants reported tinnitus during
salsalate therapy, and there were no changes in indices of
insulin sensitivity or lipid proﬁle. Nevertheless, salsalate
reduced 11b-HSD1 mRNA levels in subcutaneous adipose,
an effect which was unrelated to BMI (Fig. 4) or plasma
salicylate levels (data not shown). This was accompanied
by reduced transcript levels for MCP-1 (33.6 6 5.6% sup-
pression, P , 0.02), but not TNF-a or AdiQ. The effect of
salsalate on 11b-HSD1 activity appeared restricted to adi-
pose tissue since there was no change in ﬁrst pass con-
version of cortisone to cortisol in liver or in the ratio of
cortisol to cortisone metabolites in urine (Fig. 4).
Salicylate-induced upregulation of AdiQ is mediated
by reduced 11b-HSD1 in human adipocytes. In fully
differentiated human SGBS adipocytes, 24-h incubation
with salicylic acid in the absence of steroid dose de-
pendently reduced 11b-HSD1 mRNA levels (Fig. 5A) but
had no effect on AdiQ mRNA (Fig. 5B). Both cortisol and
cortisone treatment (0.1 mmol/L for 24 h) reduced mRNA
TABLE 1
Effects of salicylate on body weight and fasting plasma biochemistry in mice, with biochemical indices, age, high-fat diet duration, and
weight measurements for cohorts of mice
C57Bl/6 Lean C57Bl/6 DIO HSD1KO-DIO
Vehicle Salicylate Vehicle Salicylate Vehicle Salicylate
Weight at start (g) 28.8 6 0.6 29.2 6 0.5 38.4 6 1.1 39.7 6 1.7 38.0 6 0.8 38.3 6 0.5
Weight at end (g) 29.2 6 0.8 29.5 6 0.7 39.0 6 1.4 40.3 6 2.3 38.0 6 0.8 39.0 6 0.8
Age at end (weeks) 17.0 6 0.0 17.0 6 0.0 24.0 6 0.0 24.0 6 0.0 22.7 6 3.3 22.7 6 3.3
Time on HFD (weeks) 0 0 10.0 6 0 10.0 6 0 10.8 6 0.8 10.8 6 0.8
Fasting plasma
Insulin (ng/mL) 0.95 6 0.11 1.45 6 0.20* 2.69 6 0.28### 2.74 6 0.32 2.01 6 0.15v### 2.65 6 0.45
Glucose (mg/dL) 112.5 6 7.8 113.2 6 7.1 131.7 6 12.2 109.0 6 5.7* 119.5 6 4.4 119.3 6 7.5
Triglycerides (mmol/L) 0.59 6 0.04 0.63 6 0.04 0.83 6 0.04## 0.70 6 0.05 0.84 6 0.05 0.81 6 0.04
Data are mean 6 SEM for n = 7–8 per group. Comparisons were by two-way ANOVA with Bonferroni post hoc tests. HFD, high-fat diet. *P ,
0.05 vs. vehicle of same group. ##P, 0.01 vs. C57Bl/6 Lean vehicle. ###P, 0.001 vs. C57Bl/6 Lean vehicle. фP, 0.05 vs. C57Bl/6 DIO vehicle.
FIG. 1. Effects of salicylate on insulin sensitivity in C57Bl/6 Lean and DIO mice. Plasma glucose (A and C) and insulin (B and D) after in-
traperitoneal glucose injection in C57Bl/6 Lean, C57Bl/6 DIO, and HSD1KO-DIO mice. Area under the curve (AUC) for all groups shown for glucose
(C) and insulin (D). Data are mean 6 SEM for n = 7–8 per group for individual time points. Comparisons for AUC were by two-way ANOVA with
Bonferroni post hoc tests. **P < 0.01 vs. vehicle in same group; #P < 0.05, ##P < 0.01 vs. Lean vehicle; фP < 0.05 vs. C57Bl/6 DIO vehicle.
INSULIN SENSITIZATION BY SALICYLATE VIA 11b-HSD1
792 DIABETES, VOL. 61, APRIL 2012 diabetes.diabetesjournals.org
levels of AdiQ. In the presence of cortisone, coincubation
with salicylic acid attenuated the suppression of AdiQ,
whereas salicylate had no effect on suppression of AdiQ by
cortisol (Fig. 5B).
DISCUSSION
These results identify a novel mechanism by which sali-
cylates may enhance insulin action in diet-induced obesity,
involving downregulation of adipose 11b-HSD1 expression.
This downregulation occurs selectively in adipose tissue
depots in mice and in humans in vivo, is likely mediated
directly within adipose, and is mimicked in human adipo-
cytes in culture. It is crucial that mice deﬁcient in 11b-HSD1
display similar changes in in vivo metabolism and intra-
adipose gene expression as salicylate-treated wild-type mice,
and salicylate has no additional effects on these parameters
in the absence of 11b-HSD1, implicating 11b-HSD1 as a
mediator of the beneﬁcial effects of salicylate.
The magnitude and components of the metabolic effects
of salicylate remain somewhat contentious. For example,
in humans, in addition to reports of improved insulin
sensitivity (10,6,41,7), several reports describe worsening
of insulin resistance (42–44) or attribute improved me-
tabolism to an increase in insulin concentrations (9). Here,
we conﬁrm variable efﬁcacy of salicylate in different set-
tings. In lean mice, salicylate modestly increased plasma
insulin concentration but had no other metabolic effects.
In DIO mice, salicylate lowered fasting plasma glucose
concentrations and improved glucose tolerance, as well
as reducing 11b-HSD1 in visceral adipose (omental and
mesenteric) but not subcutaneous adipose tissue. These
effects, together with the lack of change in plasma in-
sulin concentrations, are consistent with insulin sensitiza-
tion primarily in visceral adipose tissue due to reduced
local glucocorticoid regeneration by 11b-HSD1 (45,46), with
secondary improvements in insulin sensitivity in other or-
gans potentially mediated by altered adipokine secretion.
The HSD1KO-DIO mice were ,2 weeks younger than the
C57Bl/6 DIO mice, so it is highly unlikely that age-dependent
effects are responsible for the discrepancies in responses
to salicylate between groups. In contrast, in the human
study, although we did not undertake sensitive measure-
ments of insulin sensitivity, such as euglycemic clamps,
there were no measured effects of salsalate on fasting in-
sulin or lipid proﬁle; this was the case even if we examined
only obese participants (not shown). It may be that high
doses are required to induce robust insulin sensitization in
humans: the salicylate concentrations achieved in this
study (mean 134 mg/L, ;1 mmol/L) (Table 2) are lower
than in some other studies (e.g., 270 mg/L) (41). This in-
consistency is in keeping with a mechanism of action
mediated by 11b-HSD1 downregulation, since recent
phase 2 clinical trials of selective 11b-HSD1 inhibitors
demonstrate that metabolic effects are of relatively small
magnitude and not always statistically signiﬁcant (26,47).
Previous studies demonstrating efﬁcacy of salicylates in
rodents use genetic models of obesity, including Zucker
obese rats and ob/ob mice (32,2,18,3). To our knowledge,
this is the ﬁrst study to demonstrate the insulin-sensitizing
FIG. 2. Effects of salicylate on 11b-HSD1 in DIO mice. 11b-HSD1 mRNA
expression in tissues from C57Bl/6 DIO mice (A). 11b-HSD1 enzyme
activity in mesenteric and subcutaneous adipose tissue fromC57Bl/6 DIO
mice (B). Om, omental; Mes, mesenteric; SC, subcutaneous. Data are
mean 6 SEM for n = 4–8 per group. Comparisons were by Student un-
paired t tests. *P < 0.05, **P < 0.01 vs. vehicle in same tissue.
FIG. 3. Effects of salicylate on adipose mRNA levels in mice. mRNA
levels were measured for AdiQ, TNF-a, MCP-1, lipoprotein lipase
(LPL), adipose triglyceride lipase (ATGL), and angiotensinogen (AGT)
by qPCR in omental (A), mesenteric (B), and subcutaneous (C) adipose
tissue from C57Bl/6 DIO and HSD1KO-DIO mice. Data are mean 6 SEM
for n = 4–8 per group. Comparisons were by two-way ANOVA with Bon-
ferroni post hoc tests. *P< 0.05, **P< 0.01 vs. vehicle of same genotype;
фP < 0.05, ффP < 0.01, фффP < 0.001 vs. C57Bl/6 DIO vehicle.
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effects of salicylate in a nongenetic model of obesity. In-
deed, diet-induced obesity was chosen because it is a more
relevant model to the obesity seen in humans. Furthermore,
salicylates improve insulin sensitivity during lipid-induced
insulin resistance (2,7). 11b-HSD1 activity is increased
acutely in adipose tissue by intralipid infusion (48), po-
tentially contributing to lipid-induced insulin resistance.
Blockade by salicylates of the effective increase in 11b-HSD1
activity could therefore explain its relatively selective effect
on lipid-induced insulin resistance.
Protective metabolic effects of 11b-HSD1 deﬁciency in
mice receiving a high-fat diet have been described pre-
viously (22) and are shown here to bear remarkable sim-
ilarity to the pattern of effects of salicylates on glucose
tolerance and adipose lipase expression. It might be ar-
gued that the lack of effect of salicylates in HSD1KO mice
is confounded by the improved metabolic “baseline” in
these animals. However, to avoid this, we administered
high-fat diet for long enough to achieve similar body
weight in HSD1KO mice to that observed in C57Bl/6 DIO
mice and, thus, ensured these HSD1KO-DIO mice were
markedly hyperinsulinemic compared with lean mice. The
striking lack of efﬁcacy of salicylate treatment in HSD1KO
mice is therefore consistent with downregulation of 11b-
HSD1 playing a key role in its mechanism of action.
Downregulation of 11b-HSD1 by salicylates is likely to
reﬂect a direct mechanism in adipose tissue, given its
replication in an adipocyte cell line. Furthermore, we have
demonstrated in vitro that salicylic acid reverses cortisone-
mediated suppression of the insulin-sensitizing adipokine
AdiQ; since salicylic acid had no effect when the contribu-
tion of 11b-HSD1 was negated by removal of steroid or by
addition of cortisol, these data indicate that inhibition of
11b-HSD1 by salicylates mediates the altered AdiQ ex-
pression also observed in vivo. The downregulation of 11b-
HSD1 was selective for the visceral adipose depots in mice
but was evident in subcutaneous adipose in humans. Cen-
tral adipose depots exhibit greater variation in lipolytic ac-
tivity and more intense proinﬂammatory responses during
high-fat feeding and are more glucocorticoid responsive
(49). However, in humans, recent evidence suggests that
11b-HSD1 regenerates more cortisol in subcutaneous than
in visceral adipose tissue (50), suggesting species-speciﬁc
differences. Moreover, we did not ﬁnd evidence that changes
in proinﬂammatory cytokines, such as TNF-a, mediate the
effects of salicylates on 11b-HSD1 expression; the down-
regulation of TNF-a by salicylates in C57Bl/6 DIO mice, but
resistance to this effect in 11b-HSD1KO mice, suggests
that effects of salicylates on intra-adipose inﬂammation
may be a consequence rather than cause of downregulation
of 11b-HSD1. This is further supported by the downregulation
of TNF-a in the visceral adipose of 11b-HSD1KO mice com-
pared with C57Bl/6 mice. In human adipose, TNF-a mRNA
TABLE 2
Effects of salsalate on anthropometry and biochemistry in
participating men
Placebo Salsalate
Age (years) 40.1 6 10.0
BMI (kg/m2) 31.9 6 8.0 32.0 6 8.0
Waist-to-hip ratio 0.93 6 0.23 0.94 6 0.23
Percent body fat 25.9 6 6.5 26.1 6 6.5
Systolic BP (mmHg) 136.8 6 34.2 137.9 6 34.5
Diastolic BP (mmHg) 79.7 6 19.9 81.9 6 20.5
Fasting plasma
Salicylate (mg/L) ND 134 6 33*
Triglycerides (mmol/L) 1.5 6 0.4 1.3 6 0.3
Total cholesterol (mmol/L) 4.7 6 1.2 4.4 6 1.1
LDL cholesterol (mmol/L) 2.7 6 0.7 2.6 6 0.6
HDL cholesterol (mmol/L) 1.3 6 0.3 1.3 6 0.3
Glucose (mmol/L) 5.2 6 1.3 5.1 6 1.3
Insulin (mU/L) 26.5 6 6.6 23.1 6 5.8
Data are mean 6 SEM for n = 16 per group. Comparisons were by
Student paired t tests. BP, blood pressure; ND, not detected. *P ,
0.01 vs. placebo.
FIG. 4. Effect of salsalate on 11b-HSD1 in humans. Subcutaneous adi-
pose tissue 11b-HSD1 mRNA levels (A); the correlation of change in
adipose mRNA levels after salsalate with BMI (B); liver 11b-HSD1,
measured as appearance of cortisol in plasma after overnight dexa-
methasone suppression and administration of 25 mg cortisone by mouth
at time 0 (C); and urinary cortisol metabolites (D) in 16 participants in
a double-blind randomized crossover trial comparing salsalate with
placebo. Data are mean 6 SEM. Comparisons were by paired Student
t test (A and D), Pearson correlation (B), or two-way repeated-measures
ANOVA (C). *P < 0.02 vs. placebo. AU, arbitrary unit.
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did not change in association with altered 11b-HSD1 mRNA.
In the absence of cytokine-mediated regulation, more de-
tailed investigation will be required to dissect the molecular
mechanisms behind the salicylate-mediated regulation of
11b-HSD1 expression.
In conclusion, these ﬁndings suggest that the anti-
inﬂammatory agent salsalate alters glucocorticoid metabo-
lism in mice and humans in a pattern that differs between
liver and subcutaneous adipose tissue. Downregulation of
intra-adipose 11b-HSD1 may contribute to the insulin-
sensitizing effect of salicylates.
ACKNOWLEDGMENTS
This work was supported by grants from the British Heart
Foundation, the Wellcome Trust, and the Medical Research
Council.
Within the past 2 years, J.R.S. and B.R.W. have consulted
for AstraZeneca, Incyte, Roche, and Wyeth; received lecture
fees from Merck; and received research funding from
AstraZeneca and Wyeth. J.R.S. and B.R.W. are inventors
on relevant patents held by the University of Edinburgh. No
other potential conﬂicts of interest relevant to this article
were reported.
M.N. conducted the experiments, analyzed data in mice
and in vitro, and wrote the manuscript. D.E.L. and C.L.E.
conducted the experiments and analyzed data in mice and
in vitro. D.J.W., R.H.S., and R.A. conducted the experiments
and analyzed data in humans. J.R.S. and K.E.C. contributed
to discussion. B.R.W. wrote the manuscript, which was
reviewed by all authors. B.R.W. is the guarantor of this work
and, as such, had full access to all the data in the study and
takes responsibility for the integrity of the data and the
accuracy of the data analysis.
Parts of this study were presented at ENDO 2010 93rd
Annual Meeting and Expo of The Endocrine Society, San
Diego, California, 19–22 June 2010, and at the British En-
docrine Society Meeting, Manchester, U.K., 15–18 March
2010.
The authors thank the Wellcome Trust Clinical Research
Facility staff for facilitating the study; Jill Harrison, Alison
McNeilly, Carolynn Cairns, Lynne Ramage, and Ash Taylor
(all of University of Edinburgh) and the staff of the Clinical
Biochemistry Laboratory, Western General Hospital, for
technical assistance; and the staff of the Biomedical Re-
search Facility, University of Edinburgh, for help with ani-
mal care. SGBS cells were kindly provided by Prof. Martin
Wabitsch, University of Ulm, Germany, and Dr. Kerry
McInnes, University of Edinburgh.
REFERENCES
1. Rainsford KD, Buchanan WW. Aspirin versus the non-acetylated salicy-
lates. Baillieres Clin Rheumatol 1990;4:247–268
2. Kim JK, Kim YJ, Fillmore JJ, et al. Prevention of fat-induced insulin re-
sistance by salicylate. J Clin Invest 2001;108:437–446
3. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity- and diet-
induced insulin resistance with salicylates or targeted disruption of Ikk-
beta. Science 2001;293:1673–1677
4. El Midaoui A, Wu R, de Champlain J. Prevention of hypertension, hyper-
glycemia and vascular oxidative stress by aspirin treatment in chronically
glucose-fed rats. J Hypertens 2002;20:1407–1412
FIG. 5. Effects of salicylic acid on 11b-HSD1 and AdiQ mRNA levels in human cultured adipocytes. A: Human SGBS adipocytes were incubated for
24 h with salicylic acid (10, 30, and 100 mmol/L) or vehicle (V) and mRNA levels measured. B: SGBS adipocytes were incubated for 24 h with
vehicle, cortisol (0.1 mmol/L), or cortisone (0.1 mmol/L), with or without salicylic acid (100 mmol/L). Data are mean 6 SEM of results from three
experiments, each conducted in triplicate. Comparisons were by one-way ANOVA with Dunnett post hoc tests (A) or two-way ANOVA with
Bonferroni post hoc tests (B). *P < 0.05, **P < 0.01 vs. vehicle; #P < 0.05 vs. cortisone control.
M. NIXON AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 61, APRIL 2012 795
5. Barreiro GC, Prattali RR, Caliseo CT, et al. Aspirin inhibits serine phos-
phorylation of IRS-1 in muscle and adipose tissue of septic rats. Biochem
Biophys Res Commun 2004;320:992–997
6. González-Ortiz M, Martínez-Abundis E, Balcázar-Muñoz BR, Robles-
Cervantes JA. Inhibition of cyclooxygenase-1 or -2 on insulin sensitivity in
healthy subjects. Horm Metab Res 2001;33:250–253
7. Möhlig M, Freudenberg M, Bobbert T, et al. Acetylsalicylic acid improves
lipid-induced insulin resistance in healthy men. J Clin Endocrinol Metab
2006;91:964–967
8. Fleischman A, Shoelson SE, Bernier R, Goldﬁne AB. Salsalate improves
glycemia and inﬂammatory parameters in obese young adults. Diabetes
Care 2008;31:289–294
9. Koska J, Ortega E, Bunt JC, et al. The effect of salsalate on insulin action
and glucose tolerance in obese non-diabetic patients: results of a rando-
mised double-blind placebo-controlled study. Diabetologia 2009;52:385–393
10. Baron SH. Salicylates as hypoglycemic agents. Diabetes Care 1982;5:64–71
11. Goldﬁne AB, Silver R, Aldhahi W, et al. Use of salsalate to target in-
ﬂammation in the treatment of insulin resistance and type 2 diabetes. Clin
Transl Sci 2008;1:36–43
12. Goldﬁne AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE;
TINSAL-T2D (Targeting Inﬂammation Using Salsalate in Type 2 Di-
abetes) Study Team. The effects of salsalate on glycemic control in pa-
tients with type 2 diabetes: a randomized trial. Ann Intern Med 2010;152:
346–357
13. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and as-
pirin. Science 1994;265:956–959
14. Shoelson SE, Lee J, Goldﬁne AB. Inﬂammation and insulin resistance. J
Clin Invest 2006;116:1793–1801
15. Cieslik KA, Zhu Y, Shtivelband M, Wu KK. Inhibition of p90 ribosomal S6
kinase-mediated CCAAT/enhancer-binding protein beta activation and
cyclooxygenase-2 expression by salicylate. J Biol Chem 2005;280:18411–
18417
16. Wu KK. Transcription-based COX-2 inhibition: a therapeutic strategy.
Thromb Haemost 2006;96:417–422
17. Seckl JR, Walker BR. Minireview: 11beta-hydroxysteroid dehydrogenase
type 1- a tissue-speciﬁc ampliﬁer of glucocorticoid action. Endocrinology
2001;142:1371–1376
18. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral
obesity and the metabolic syndrome. Science 2001;294:2166–2170
19. Paterson JM, Morton NM, Fievet C, et al. Metabolic syndrome without
obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase
type 1 in transgenic mice. Proc Natl Acad Sci U S A 2004;101:7088–7093
20. Kotelevtsev Y, Holmes MC, Burchell A, et al. 11beta-hydroxysteroid
dehydrogenase type 1 knockout mice show attenuated glucocorticoid-
inducible responses and resist hyperglycemia on obesity or stress. Proc
Natl Acad Sci U S A 1997;94:14924–14929
21. Morton NM, Holmes MC, Fiévet C, et al. Improved lipid and lipoprotein
proﬁle, hepatic insulin sensitivity, and glucose tolerance in 11beta-
hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 2001;276:
41293–41300
22. Morton NM, Paterson JM, Masuzaki H, et al. Novel adipose tissue-mediated
resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid de-
hydrogenase type 1-deﬁcient mice. Diabetes 2004;53:931–938
23. Walker BR, Connacher AA, Lindsay RM, Webb DJ, Edwards CR. Carbe-
noxolone increases hepatic insulin sensitivity in man: a novel role for
11-oxosteroid reductase in enhancing glucocorticoid receptor activation.
J Clin Endocrinol Metab 1995;80:3155–3159
24. Hermanowski-Vosatka A, Balkovec JM, Cheng K, et al. 11beta-HSD1 in-
hibition ameliorates metabolic syndrome and prevents progression of
atherosclerosis in mice. J Exp Med 2005;202:517–527
25. Hughes KA, Webster SP, Walker BR. 11-Beta-hydroxysteroid dehydrogenase
type 1 (11beta-HSD1) inhibitors in type 2 diabetes mellitus and obesity.
Expert Opin Investig Drugs 2008;17:481–496
26. Rosenstock J, Banarer S, Fonseca VA, et al.; INCB13739-202 Principal In-
vestigators. The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor
INCB13739 improves hyperglycemia in patients with type 2 diabetes in-
adequately controlled by metformin monotherapy. Diabetes Care 2010;33:
1516–1522
27. Tomlinson JW, Moore J, Cooper MS, et al. Regulation of expression of
11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-
speciﬁc induction by cytokines. Endocrinology 2001;142:1982–1989
28. Hardy RS, Filer A, Cooper MS, et al. Differential expression, function and
response to inﬂammatory stimuli of 11beta-hydroxysteroid dehydrogenase
type 1 in human ﬁbroblasts: a mechanism for tissue-speciﬁc regulation of
inﬂammation. Arthritis Res Ther 2006;8:R108
29. Balachandran A, Guan H, Sellan M, van Uum S, Yang K. Insulin and
dexamethasone dynamically regulate adipocyte 11beta-hydroxysteroid
dehydrogenase type 1. Endocrinology 2008;149:4069–4079
30. Stewart PM, Boulton A, Kumar S, Clark PM, Shackleton CH. Cortisol
metabolism in human obesity: impaired cortisone—.cortisol conversion
in subjects with central adiposity. J Clin Endocrinol Metab 1999;84:1022–
1027
31. Rask E, Olsson T, Söderberg S, et al. Tissue-speciﬁc dysregulation of
cortisol metabolism in human obesity. J Clin Endocrinol Metab 2001;86:
1418–1421
32. Livingstone DE, Jones GC, Smith K, et al. Understanding the role of glu-
cocorticoids in obesity: tissue-speciﬁc alterations of corticosterone me-
tabolism in obese Zucker rats. Endocrinology 2000;141:560–563
33. Wake DJ, Rask E, Livingstone DE, Söderberg S, Olsson T, Walker BR.
Local and systemic impact of transcriptional up-regulation of 11beta-
hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity.
J Clin Endocrinol Metab 2003;88:3983–3988
34. Walker BR. Extra-adrenal regeneration of glucocorticoids by 11beta-
hydroxysteroid dehydrogenase type 1: physiological regulator and phar-
macological target for energy partitioning. Proc Nutr Soc 2007;66:1–8
35. Baudrand R, Carvajal CA, Riquelme A, et al. Overexpression of 11beta-
hydroxysteroid dehydrogenase type 1 in hepatic and visceral adipose tis-
sue is associated with metabolic disorders in morbidly obese patients.
Obes Surg 2010;20:77–83
36. Veilleux A, Rhéaume C, Daris M, Luu-The V, Tchernof A. Omental adipose
tissue type 1 11 beta-hydroxysteroid dehydrogenase oxoreductase activity,
body fat distribution, and metabolic alterations in women. J Clin Endo-
crinol Metab 2009;94:3550–3557
37. Sandeep TC, Andrew R, Homer NZ, Andrews RC, Smith K, Walker BR.
Increased in vivo regeneration of cortisol in adipose tissue in human
obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1
inhibitor carbenoxolone. Diabetes 2005;54:872–879
38. Sutinen J, Kannisto K, Korsheninnikova E, et al. In the lipodystrophy
associated with highly active antiretroviral therapy, pseudo-Cushing’s
syndrome is associated with increased regeneration of cortisol by 11beta-
hydroxysteroid dehydrogenase type 1 in adipose tissue. Diabetologia 2004;
47:1668–1671
39. Wabitsch M, Brenner RE, Melzner I, et al. Characterization of a human
preadipocyte cell strain with high capacity for adipose differentiation. Int
J Obes Relat Metab Disord 2001;25:8–15
40. Best R, Walker BR. Additional value of measurement of urinary cortisone
and unconjugated cortisol metabolites in assessing the activity of 11 beta-
hydroxysteroid dehydrogenase in vivo. Clin Endocrinol (Oxf) 1997;47:231–
236
41. Hundal RS, Petersen KF, Mayerson AB, et al. Mechanism by which high-
dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest
2002;109:1321–1326
42. Giugliano D, Sacca L, Scognamiglio G, Ungaro B, Torella R. Inﬂuence of
acetylsalicylic acid on glucose turnover in normal man. Diabete Metab
1982;8:279–282
43. Newman WP, Brodows RG. Aspirin causes tissue insensitivity to insulin in
normal man. J Clin Endocrinol Metab 1983;57:1102–1106
44. Bratusch-Marrain PR, Vierhapper H, Komjati M, Waldhäusl WK. Acetyl-
salicylic acid impairs insulin-mediated glucose utilization and reduces
insulin clearance in healthy and non-insulin-dependent diabetic man.
Diabetologia 1985;28:671–676
45. Tomlinson JW, Sherlock M, Hughes B, et al. Inhibition of 11beta-
hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid
exposure to human adipose tissue and decreases lipolysis. J Clin Endocrinol
Metab 2007;92:857–864
46. Macfarlane DP, Forbes S, Walker BR. Glucocorticoids and fatty acid me-
tabolism in humans: fuelling fat redistribution in the metabolic syndrome.
J Endocrinol 2008;197:189–204
47. Feig PU, Shah S, Hermanowski-Vosatka A, et al. Effects of an 11b-
hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients
with type 2 diabetes mellitus and metabolic syndrome. Diabetes Obes
Metab 2011;13:498–504
48. Wake DJ, Homer NZ, Andrew R, Walker BR. Acute in vivo regulation of
11beta-hydroxysteroid dehydrogenase type 1 activity by insulin and in-
tralipid infusions in humans. J Clin Endocrinol Metab 2006;91:4682–4688
49. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation
to the metabolic syndrome. Endocr Rev 2000;21:697–738
50. Stimson RH, Andersson J, Andrew R, et al. Cortisol release from adipose
tissue by 11beta-hydroxysteroid dehydrogenase type 1 in humans. Di-
abetes 2009;58:46–53
INSULIN SENSITIZATION BY SALICYLATE VIA 11b-HSD1
796 DIABETES, VOL. 61, APRIL 2012 diabetes.diabetesjournals.org
